Home · Health · Aug 26 archive
FDA Approves Daraxonrasib for Pancreatic Cancer
Developing
In Short: The U.S. Food and Drug Administration has approved daraxonrasib, a first-of-its-kind pill to treat metastatic pancreatic cancer, marking a significant advance in cancer treatment.
The U.S. Food and Drug Administration (FDA) has approved daraxonrasib, a groundbreaking new drug for metastatic pancreatic cancer, offering US patients a more effective treatment against one of the deadliest types of the disease.
Daraxonrasib is the first-of-a-kind pill that blocks a mutated protein which fuels tumor growth in more than 90% of pancreatic cancer cases, according to FDA officials.
The FDA expedited the approval process, approving the drug more than six months ahead of their target date, highlighting their commitment to delivering meaningful treatments to patients as quickly as possible, said the FDA’s acting commissioner, Kyle Diamantas.
This approval represents a significant advance in cancer treatment, as it is the first RAS inhibitor drug to be approved for the most common form of pancreatic cancer.
What's confirmed
What's still developing
- FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of cancer FDA officials approve first-of-a-kind pill called daraxonrasib to fight one of the deadliest types of…
- FDA officials gave expedited approval to the first-of-a-kind pill, called daraxonrasib, that blocks a mutated protein which fuels tumor growth in more than 90% of pancreatic cancer cases.
- FDA regulators noted on Wednesday that they approved the drug more than six months ahead of their target date.
- “It is our fundamental duty to deliver more cures and meaningful treatments to patients as quickly as possible,” the FDA’s acting commissioner, Kyle Diamantas, said in a statement.
Sources
- The Guardianlink